Fifth bivalent omicron BA.4/BA.5 vaccination neutralization of SARS-CoV-2 in heart transplant recipients

被引：2

作者：

Peled, Yael ^{[1
,2
,5
]}

Afek, Arnon ^{[1
,2
]}

Patel, Jignesh K. ^{[3
]}

Raanani, Ehud ^{[1
,2
]}

Segev, Amit ^{[1
,2
]}

Ram, Eilon ^{[1
,2
]}

Fardman, Alexander ^{[1
,2
]}

Beigel, Roy ^{[1
,2
]}

Atari, Nofar ^{[4
]}

Kliker, Limor ^{[4
]}

Abd Elkader, Bayan ^{[4
]}

Mandelboim, Michal ^{[2
,4
]}

机构：

[1] Sheba Med Ctr, Leviev Cardiothorac & Vasc Ctr, Ramat Gan, Israel

[2] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel

[3] Cedars Sinai Heart Inst, Los Angeles, CA USA

[4] Minist Hlth, Cent Virol Lab, Tel Hashomer, Israel

[5] Sheba Med Ctr, Leviev Cardiothorac & Vasc Ctr, IL-52621 Ramat Gan, Israel

来源：

JOURNAL OF HEART AND LUNG TRANSPLANTATION | 2023年 / 42卷 / 08期

关键词：

bivalent vaccine; heart transplantation; fifth dose; SARS-CoV-2; neutralization;

D O I：

10.1016/j.healun.2023.03.016

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In 2022, the antigenically divergent SARS-CoV-2 omicron variants (BA.1, BA.2, BA.4, BA.5) outcompeted previous variants and continued to cause substantial numbers of illnesses and deaths. We evaluated the safety and immunogenicity of the bivalent original/omicron BA.4/ BA.5 Pfizer/BioNTech vaccine administered as a fifth dose to heart transplant recipients (HTxRs). We compared neutralization (using live virus assays) of SARS-CoV-2-infected cells in serum samples from HTxRs who had previously received 4 doses of the monovalent BNT162b2 vaccine with samples from HTxRs with breakthrough infection after 4 monovalent BNT162b2 doses. The fifth vaccination induced high neutralization efficiency against the wild-type virus and omicron BA.1, BA.2, BA.4, and BA.5 variants, with significantly higher neutralization efficiency being induced in HTxRs with breakthrough infection than in those without. Neutralizing titers in those with breakthrough infection were sustained above the level induced by the fifth dose in the uninfected. We conclude that the fifth bivalent vaccine is immunogenic, including to variants, with higher vaccine immunogenicity conferred by breakthrough infection. Nevertheless, the clinical protection conferred by the fifth dose is yet to be determined. The sustained neutralization responses in those with breakthrough infection support the notion of delaying booster in those with natural breakthrough infection. J Heart Lung Transplant 2023;42:1054-1058 & COPY; 2023 International Society for Heart and Lung Transplantation. All rights reserved.

引用

页码：1054 / 1058

页数：5